[Asia Economy Reporter Oh Ju-yeon] Intrivo, the US sales distributor of Access Bio, a specialized in vitro diagnostic company, has signed distribution agreements with global pharmaceutical distributors to expand sales of its COVID-19 antigen rapid test kits. Through this agreement, Access Bio plans to expand the supply network of COVID-19 antigen rapid test kits across the United States.
On the 4th, Access Bio announced that Intrivo, its US sales distributor, signed contracts with Concordance Healthcare Solutions and NDC for the sales of Access Bio's COVID-19 antigen rapid test kits.
Liv Vernaron, CEO of Intrivo, stated, "This will be very meaningful not only for Access Bio and Intrivo but also for medical institutions and patients. If the distribution of Access Bio's products is greatly expanded through new distribution channels and accessibility to on-site testing improves, it will greatly help control the spread of COVID-19."
Concordance Healthcare Solutions and NDC are major medical device distributors in the United States. Access Bio said, "Distribution and marketing cooperation with global companies will be a good stepping stone to expand Access Bio's COVID-19 diagnostic products throughout the US."
Choi Young-ho, CEO of Access Bio, said, "By expanding product distribution through this agreement, we will increase the testing rate and contribute to the US returning to normal life. Our products will play a very important role not only in confirming current COVID-19 infections but also in verifying the efficacy of vaccines to be distributed in the future."
Meanwhile, Wooridul Pharmaceutical is the largest shareholder of Access Bio, holding a 25.26% stake.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
